New York State Approves Precipio's HemeScreen for POL clinical use

Stock Information for Precipio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Precipio Inc.

Precipio Announces Year end 2023 Shareholder Update Call
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
Precipio Announces Christina Valauri joins the Board of Directors
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
Precipio Announces Q3-2023 Shareholder Update Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.